Entera Bio Ltd. 8K

Entera Bio Ltd. agreed to a private placement of ordinary shares and pre-funded warrants to institutional investors for at least $210 million in gross proceeds under a July 26, 2026 Securities Purchase Agreement.

Entera Bio Ltd. entered into a Securities Purchase Agreement dated July 26, 2026 with multiple institutional investors, including BVF Partners L.P. and its affiliates, for a private placement of ordinary shares and pre-funded warrants at a per share purchase price of $2.04, with the investors’ aggregate subscription amount required to be at least $210 million as a condition to closing. The transaction will close remotely within five business days subject to customary representations, warranties, closing deliveries, regulatory and stock exchange approvals, minimum aggregate proceeds, and an absence of material adverse effects or trading suspensions, and is being executed as an exempt offering under Section 4(a)(2) of the Securities Act and Rule 506, with associated registration rights granted to the investors for resale of the shares and warrant shares. Placement agents including Leerink Partners, Evercore, Guggenheim Securities, Cantor Fitzgerald, LifeSci Capital and Canaccord Genuity are engaged for the offering, and the company makes extensive representations regarding its capitalization, SEC compliance, listing status, internal controls, intellectual property, and regulatory and tax compliance in connection with the financing.

Filing Facts

CIK

1638097

Ticker

-

Form

8K

Source Type

sec

Accession

0001178913-26-003617

Alert Tier

8